Kanazawa N, Okafuji I, Kambe N, Nishikomori R, Nakata-Hizume M, Nagai S, et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood. 2005;105:1195–7.
Article
CAS
Google Scholar
Shetty AK, Gedalia A. Sarcoidosis: a pediatric perspective. Clin Pediatr (Phila). 1998;37:707–17.
Article
CAS
Google Scholar
Miceli-Richard C, Lesage S, Rybojad M, Prieur AM, Manouvrier-Hanu S, Häfner R, et al. CARD15 mutations in Blau syndrome. Nat Genet. 2001;29:19–20.
Article
CAS
Google Scholar
Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr Rheumatol Rep. 2005;7:427–33.
Article
CAS
Google Scholar
Rose CD, Wouters CH, Meiorin S, Doyle TM, Davey MP, Rosenbaum JT, et al. Pediatric granulomatous arthritis: an international registry. Arthritis Rheum. 2006;54:3337–44.
Article
Google Scholar
Aróstegui JI, Arnal C, Merino R, Modesto C, Carballo MA, Moreno P, et al. NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56:3805–13.
Article
Google Scholar
Sfriso P, Caso F, Tognon S, Galozzi P, Gava A, Punzi L. Blau syndrome, clinical and genetic aspects. Autoimmun Rev. 2012;12:44–51.
Article
CAS
Google Scholar
Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, et al. Blau syndrome-associated uveitis: preliminary results from an international prospective interventional case series. Am J Ophthalmol. 2018;187:158–66.
Article
Google Scholar
Achille M, Ilaria P, Teresa G, Roberto C, Ilir A, Piergiorgio N, et al. Successful treatment with adalimumab for severe multifocal choroiditis and panuveitis in presumed (early-onset) ocular sarcoidosis. Int Ophthalmol. 2016;36:129–35.
Article
Google Scholar
Tanabe T, Chamaillard M, Ogura Y, Zhu L, Qiu S, Masumoto J, et al. Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition. EMBO J. 2004;23:1587–97.
Article
CAS
Google Scholar
Yamaguchi N, Suzuki Y, Mahbub MH, Takahashi H, Hase R, Ishimaru Y, et al. The different roles of innate immune receptors in inflammation and carcinogenesis between races. Environ Health Prev Med. 2017;22:70.
Article
Google Scholar
Akahoshi M, Ishihara M, Namba K, Kitaichi N, Ando Y, Takenaka S, et al. Mutation screening of the CARD15 gene in sarcoidosis. Tissue Antigens. 2008;71:564–7.
Article
CAS
Google Scholar
Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J, Schwinger E, Schreiber S. CARD15 gene mutations in sarcoidosis. Eur Respir J. 2003;22:748–54.
Article
CAS
Google Scholar
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem. 2003;278:8869–72.
Article
CAS
Google Scholar
Eishi Y. Etiologic aspect of sarcoidosis as an allergic endogenous infection caused by Propionibacterium acnes. Biomed Res Int. 2013;2013:935289.
Article
Google Scholar
Fink CW, Cimaz R. Early onset sarcoidosis: not a benign disease. J Rheumatol. 1997;24:174–7.
CAS
PubMed
Google Scholar
Negi M, Takemura T, Guzman J, Uchida K, Furukawa A, Suzuki Y, et al. Localization of Propionibacterium acnes in granulomas supports a possible etiologic link between sarcoidosis and the bacterium. Mod Pathol. 2012;25:1284–97.
Article
CAS
Google Scholar
Matsuda T, Kambe N, Ueki Y, Kanazawa N, Izawa K, Honda Y, et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann Rheum Dis. 2020. doi:https://doi.org/10.1136/annrheumdis-2020-217320.
Article
PubMed
Google Scholar
Milman N, Ursin K, Rødevand E, Nielsen FC, Hansen TVO. A novel mutation in the NOD2 gene associated with Blau syndrome: a Norwegian family with four affected members. Scand J Rheumatol. 2009;38:190–7.
Article
CAS
Google Scholar
Rosé CD, Aróstegui JI, Martin TM, Espada G, Scalzi L, Yagüe J, Rosenbaum JT, et al. NOD2-associated pediatric granulomatous arthritis, an expanding phenotype: Study of an International Registry and a National Cohort in Spain. Arthritis Rheum. 2009;60:1797–803.
Article
Google Scholar
Yamada T, Eishi Y, Ikeda S, Ishige I, Suzuki T, Takemura T, et al. In situ localization of Propionibacterium acnes DNA in lymph nodes from sarcoidosis patients by signal amplification with catalysed reporter deposition. J Pathol. 2002;198:541–7.
Article
CAS
Google Scholar
Asahina A, Miura K, Saito I, Oshikata C, Ishii N, Eishi Y. Cutaneous sarcoidosis with livedoid lesions: evidence of the involvement of Propionibacterium acnes. J Dermatol. 2013;40:501–2.
Article
Google Scholar
Takama H, Yanagishista T, Muto J, Ohshima Y, Takahashi E, Tsuzuki T, et al. Granulomatous pigmented purpuric dermatosis containing Propionibacterium acnes. Eur J Dermatol. 2018;28:540–2.
Article
Google Scholar
Sasaki S, Kato M, Nakamura K, Namba Y, Nagashima O, Takahashi K. Management of skin sarcoidosis with minocycline monotherapy. Respirol Case Rep. 2019;7:e00413.
PubMed
PubMed Central
Google Scholar
Noda S, Maeda A, Komiya Y, Soejima M. A Patient with necrotizing vasculitis related to sarcoidosis, which was diagnosed via immunohistochemical methods using P. acnes-specific monoclonal antibodies. Intern Med. 2020;10:4918–20.
Google Scholar
Inoue Y, Teraki Y. Association of Propionibacterium acnes with the efficacy of minocycline therapy for cutaneous sarcoidosis. Int J Dermatol. 2020;59:704–8.
Article
CAS
Google Scholar
Nagata K, Eishi Y, Uchida K, Yoneda K, Hatanaka H, Yasuhara T, et al. Immunohistochemical detection of Propionibacterium acnes in the retinal granulomas in patients with ocular sarcoidosis. Sci Rep. 2017;7:15226.
Article
Google Scholar
Tanabe T, Ishige I, Suzuki Y, Aita Y, Furukawa A, Ishige Y, et al. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium Acnes. Biochim Biophys Acta. 2006;1762:794–801.
Article
CAS
Google Scholar
Nagakura T, Wakiguchi H, Kubota T, Yamatou T, Yamasaki Y, Nonaka Y, et al. Tumor necrosis factor inhibitors provide longterm clinical benefits in pediatric and young adult patients with Blau syndrome. J Rheumatol. 2017;44:536–8.
Article
CAS
Google Scholar